Gene mutations in TP53 are predominantly associated with EGFR mutations [31] and KRAS mutations [32,33] in NSCLC patients and are indicators for unfavorable progression-free and overall survival [34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.